Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Barretos Cancer Hospital
With
University of Sao Paulo
Locally advanced breast cancer is a common condition in development countries. Neoadjuvant chemotherapy gives the opportunity to identify genetic signatures associated with objective clinical and pathological complete responses.
Patients will receive doxorubicin/cyclophosphamide with paclitaxel. Tumor samples collected before and after chemotherapy will be analyzed.
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women with locally advanced women breast cancer
Histology: ductal ou lobular invasive histology
Agreement to take part in the study and signature of the informed consent
Clinical condition to receive doxorubicin/cyclophosphamide and paclitaxel
ECOG 0 or I
You may not be if
Not clinical stage III
Inflammatory breast cancer
Previous treatment
Previous diagnosis of cancer (except basal cell or squamous cell skin carcinoma and non-invasive cervical carcinoma)
Pregnancy
Absence of clinical condition to receive chemotherapy
Clareo Health | Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
